Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer

Completed · Phase 2

Conditions studied: Breast Cancer

In brief

This is a two arm, double-blind randomized study looking at the effect of zoledronate, a bisphosphonate, on the bone mineral density (BMD) of postmenopausal women with breast cancer.

Key facts

Study ID

NCT00213980

Run by

University of Wisconsin, Madison

People needed

68

Starts

2000-01-01

Expected to finish

2008-04-01

Last updated by the study team

2019-11-27

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Postmenopausal women, Stage III or axillary node positive
• Currently disease free of breast cancer and other invasive malignancies at the time of registration
• No concurrent use of bisphosphonates

You may not qualify if…

• Metastatic disease

Where it is running

• University of Wisconsin — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.